Sequana Medical has reportedly announced strong interim results from the first five patients registered in its RED DESERT study. The research focuses on the assessment of continual dose treatment of alfapump Direct Sodium Removal amongst patients diagnosed with diuretic-resistant heart failure.
Reports cite that the restoration of diuretic response as an explanatory endpoint of the study has been achieved through a six-hour long excretion of sodium and fluid, carried out after intravenously administering 40mg of furosemide. The RED DESERT recorded all patients to have a fairly poor diuretic response at the baseline.
However, following a